00:43 , Jan 13, 2018 |  BioCentury  |  Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market...
20:23 , Nov 3, 2017 |  BC Week In Review  |  Financial News

Allena raises $74.7M IPO

On Nov. 1, kidney disease company Allena Pharmaceuticals Inc. (NASDAQ:ALNA) raised $74.7 million through the sale of 5.3 million shares at $14 in an IPO underwritten by Credit Suisse, Jefferies, Cowen and Wedbush PacGrow. The...
16:31 , Nov 2, 2017 |  BC Extra  |  Financial News

Spero sags after $77M listing

Spero Therapeutics Inc. (NASDAQ:SPRO) sank $2.50 (18%) to $11.50 on Thursday after raising $77 million through the sale of 5.5 million shares at $14 in an IPO underwritten by BofA Merrill Lynch, Cowen, Stifel and...
15:10 , Nov 2, 2017 |  BC Extra  |  Financial News

Allena slips after pricing $74.7M IPO

Allena Pharmaceuticals Inc. (NASDAQ:ALNA) dipped $4.02 (29%) to $9.98 on Thursday after it raised $74.7 million through the sale of 5.3 million shares at $14 in an IPO underwritten by Credit Suisse, Jefferies, Cowen and...
19:51 , Oct 13, 2017 |  BC Week In Review  |  Financial News

Allena proposes $92M IPO

Kidney disease company Allena Pharmaceuticals Inc. (Newton, Mass.) proposed to raise up to $92 million on Oct. 6 in an IPO on NASDAQ underwritten by Credit Suisse, Jefferies, Wedbush and Cowen. Allena's lead candidate, ALLN-177...
19:53 , Oct 9, 2017 |  BC Extra  |  Financial News

Allena proposes $92M IPO

Kidney disease company Allena Pharmaceuticals Inc. (Newton, Mass.) proposed to raise up to $92 million in an IPO on NASDAQ underwritten by Credit Suisse, Jefferies, Wedbush and Cowen. Allena's lead candidate, ALLN-177 , is an...
23:29 , Oct 6, 2017 |  BioCentury  |  Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
08:00 , Feb 15, 2016 |  BC Week In Review  |  Clinical News

ALLN-177: Phase II started

Allena began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 7,500 units of oral ALLN-177 thrice daily with meals for 28 days in about 44 patients. Allena Pharmaceuticals Inc. , Newton, Mass.   Product:...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Financial News

Allena Pharmaceuticals completes venture financing

Allena Pharmaceuticals Inc. , Newton, Mass.   Business: Endocrine/Metabolic   Date completed: 2015-12-09   Type: Venture financing   Raised: $53 million   Investors: Partner Fund Management; Fidelity; Wellington Management; Frazier Healthcare; HBM BioCapital; Pharmstandard International...
02:35 , Dec 10, 2015 |  BC Extra  |  Financial News

Allena's series C round brings $53M

Allena Pharmaceuticals Inc. (Newton, Mass.) raised $53 million in a series C financing led by Partner Fund Management. New investors Fidelity and Wellington Management also participated, along with existing investors Frazier Healthcare, HBM BioCapital and...